Elspar (Merck & Co. Inc)
Elspar (Merck & Co. Inc) Brand names, Elspar (Merck & Co. Inc) Analogs
Elspar (Merck & Co. Inc) Brand Names Mixture
- No information avaliable
Elspar (Merck & Co. Inc) Chemical_Formula
C1377H2208N382O442S17
Elspar (Merck & Co. Inc) RX_link
http://www.rxlist.com/cgi/generic3/asparaginase.htm
Elspar (Merck & Co. Inc) fda sheet
Elspar (Merck & Co. Inc) msds (material safety sheet)
Elspar (Merck & Co. Inc) Synthesis Reference
No information avaliable
Elspar (Merck & Co. Inc) Molecular Weight
31731.9
Elspar (Merck & Co. Inc) Melting Point
No information avaliable
Elspar (Merck & Co. Inc) H2O Solubility
No information avaliable
Elspar (Merck & Co. Inc) State
Liquid
Elspar (Merck & Co. Inc) LogP
0.059
Elspar (Merck & Co. Inc) Dosage Forms
Powder for solution; Solution (IV or IM injection)
Elspar (Merck & Co. Inc) Indication
For treatment of acute lympocytic leukemia and non-Hodgkins lymphoma
Elspar (Merck & Co. Inc) Pharmacology
In a significant number of patients with acute leukemia, the malignant cells are dependent on an exogenous source of asparagine for survival. Normal cells, however, are able to synthesize asparagine and thus are affected less by the rapid depletion produced by treatment with the enzyme asparaginase. Elspar exploits a metabolic defect in asparagine synthesis of some malignant cells.
Elspar (Merck & Co. Inc) Absorption
No information avaliable
Elspar (Merck & Co. Inc) side effects and Toxicity
No information avaliable
Elspar (Merck & Co. Inc) Patient Information
No information avaliable
Elspar (Merck & Co. Inc) Organisms Affected
Humans and other mammals
